首页> 外文期刊>BioProcess International >Demonstrating Intactness of Biopharmaceutical Products: Intact Molecular-Weight Analysis and Terminal Sequencing of Proteins
【24h】

Demonstrating Intactness of Biopharmaceutical Products: Intact Molecular-Weight Analysis and Terminal Sequencing of Proteins

机译:展示生物制药产品的完整性:完整的分子量分析和蛋白质末端测序

获取原文
获取原文并翻译 | 示例
           

摘要

Regulations require that biomanufacturers assess the intactness of protein and glycoprotein products as well as confirm the terminal sequences to look for existing variations. ICH Q6B guideline section 6.1.1 c statesTerminal amino acid analysis is performed to identify the nature and homogeneity of the amino- and carboxy-terminal amino acids. If the desired product is found to be heterogeneous with respect to the terminal amino acids, the relative amounts of the variant forms should be determined using an appropriate analytical procedure. The sequence of these terminal amino acids should be compared with the terminal amino acid sequence deduced from the gene sequence of the desired product.
机译:法规要求生物制造商评估蛋白质和糖蛋白产品的完整性以及确认终端序列以寻找现有的变化。 ICH Q6B指南第6.1.1条C统计氨基酸分析鉴定氨基和羧酸末端氨基酸的性质和均匀性。 如果发现所需产物相对于末端氨基酸是非均相的,则应使用适当的分析方法确定变体形式的相对量。 应将这些末端氨基酸的序列与从所需产物的基因序列推导的末端氨基酸序列进行比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号